This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Jeremy Manheim, Ph.D.
Associate Principal Scientist at Merck
Speaker

Profile

Dr. Jeremy Manheim earned his PhD in Chemistry from Purdue University in 2020 where he specialized in mass spectrometry. He is currently an associate principal scientist in the small molecule analytical research and development department at Merck. His research interests span small and large molecule analyses and developing mass spectrometry-based methods for pharmaceutical samples. Additionally, he has worked closely with peers in both academia and industry to improve the characterization and control strategy for peptide API. He is also an active member of the international consortium for innovation and quality in pharmaceutical development (IQ) Peptide Working Group NDA/BLA sub team.

Agenda Sessions

  • Perspective on Current Industry Control Strategies for Synthetic Peptides

    2:00pm